Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

pomalidomide

View Patient Information
An orally bioavailable derivative of thalidomide with potential immunomodulating, antiangiogenic and antineoplastic activities. Although its exact mechanism of action has yet to be fully elucidated, pomalidomide appears to inhibit TNF-alpha production, enhance the activity of T cells and natural killer (NK) cells and enhance antibody-dependent cellular cytotoxicity (ADCC). In addition, pomalidomide may inhibit tumor angiogenesis, promote cell cycle arrest in susceptible tumor cell populations, and stimulate erythropoeisis.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:4-aminothalidomide
US brand name:Actimid
Pomalyst
Foreign brand name:Imnovid
Code name:CC-4047
CC4047
Chemical structure:3-amino-N-(2,6-dioxo-3-piperidyl)phthalimide
4-amino-2-(2,6-dioxo-3-piperidyl)isoindoline-1,3-dione
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search